[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![Kaken Pharmaceutical Co. Ltd. Graphic](https://lunarcrush.com/gi/w:26/t:$4521t.png) Kaken Pharmaceutical Co. Ltd.

Kaken Pharmaceutical partners with Astria Therapeutics to develop and sell Navenibart for HAE in Japan. Alumis and Kaken Pharmaceutical announce collaboration and licensing agreement for ESK-001 in Dermatology in Japan, driving social engagement and mentions on X (formerly Twitter). 

### About Kaken Pharmaceutical Co. Ltd.
Kaken Pharmaceutical Co. Ltd. is a pharmaceutical company.  

### Price: $ [#](/topic/$4521t/close)
---
![Price Line Chart](https://lunarcrush.com/gi/w:600/t:$4521t/c:line/m:close/iv:1d.svg)  
[Price 24-Hour Time-Series Raw Data](/topic/$4521t/time-series/close.tsv)  
The price action is likely influenced by the recent licensing agreements and collaborations, particularly the partnership with Astria Therapeutics, which could be driving positive sentiment and potentially influencing the price.  

**1-Year High**: $XXXXX on 2025-03-12  
**1-Year Low**: $XXXXX on 2025-10-01  
  
  
### AltRank: undefined [#](/topic/$4521t/alt_rank)
---
![AltRank Line Chart](https://lunarcrush.com/gi/w:600/t:$4521t/c:line/m:alt_rank/iv:1d.svg)  
[AltRank 24-Hour Time-Series Raw Data](/topic/$4521t/time-series/alt_rank.tsv)  
Kaken Pharmaceutical Co. Ltd. is currently AltRank #undefined based on combined combined social and market metrics
**Daily Average**: XXXXX  
**1-Year High**: XXXXX on 2025-02-27  
**1-Year Low**: XXX on 2025-02-25  
  
  
### Galaxy Score: XX [#](/topic/$4521t/galaxy_score)
---
![Galaxy Score Line Chart](https://lunarcrush.com/gi/w:600/t:$4521t/c:line/m:galaxy_score/iv:1d.svg)  
[Galaxy Score 24-Hour Time-Series Raw Data](/topic/$4521t/time-series/galaxy_score.tsv)  
**Current Value**: XX  
**Daily Average**: XX  
**1-Year High**: XX on 2024-12-19  
**1-Year Low**: XX on 2025-02-11  
  
  
### Engagements: X [#](/topic/$4521t/interactions)
---
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$4521t/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/$4521t/time-series/interactions.tsv)  
**Current Value**: X  
**Daily Average**: XXX  
**1 Week**: XXX -XX%  
**1 Month**: XXXXX +762%  
**6 Months**: XXXXXX -XXXX%  
**1 Year**: XXXXXX +1,476%  
**1-Year High**: XXXXX on 2025-04-08  
**1-Year Low**: X on 2025-02-08  

| Social Network | YouTube | X |
| -------------- | ------- | - |
| Engagements    | X       | X |
  

  
  
### Mentions: X [#](/topic/$4521t/posts_active)
---
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$4521t/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/$4521t/time-series/posts_active.tsv)  
**Current Value**: X  
**Daily Average**: X  
**6 Months**: XX -XX%  
**1 Year**: XX +830%  
**1-Year High**: XX on 2025-03-25  
**1-Year Low**: X on 2024-11-27  

| Social Network | YouTube | X |
| -------------- | ------- | - |
| Mentions       | X       | X |
  

  
  
### Creators: X [#](/topic/$4521t/contributors_active)
---
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$4521t/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/$4521t/time-series/contributors_active.tsv)  
X unique social accounts have posts mentioning Kaken Pharmaceutical Co. Ltd. in the last XX hours which is down XX% from X in the previous XX hours
**Daily Average**: X  
**6 Months**: XX -XX%  
**1 Year**: XX +700%  
**1-Year High**: XX on 2025-03-25  
**1-Year Low**: X on 2024-11-27  
  
  
### Sentiment: % [#](/topic/$4521t/sentiment)
---
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$4521t/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$4521t/time-series/sentiment.tsv)  
**Current Value**: %  
**Daily Average**: XXX%  
**1 Week**: XXX% no change  
**1 Month**: XXX% no change  
**6 Months**: XXX% no change  
**1 Year**: XXX% no change  
**1-Year High**: XXX% on 2024-11-28  
**1-Year Low**: XXX% on 2024-11-28  
  
  
### Market Cap: $undefined [#](/topic/$4521t/market_cap)
---
![Market Cap Line Chart](https://lunarcrush.com/gi/w:600/t:$4521t/c:line/m:market_cap/iv:1d.svg)  
[Market Cap 24-Hour Time-Series Raw Data](/topic/$4521t/time-series/market_cap.tsv)  
**Current Value**: $undefined  
**Daily Average**: $XXXXXXXXXXXXXXX  
**1-Year High**: $XXXXXXXXXXXXXXX on 2025-03-12  
**1-Year Low**: $XXXXXXXXXXXXXXX on 2024-10-23  

**Top topics mentioned**
In the posts about Kaken Pharmaceutical Co. Ltd. in the last XX hours

[life of](/topic/life-of), [superior](/topic/superior), [$alms](/topic/$alms), [japan](/topic/japan), [$40m](/topic/$40m), [$atxs](/topic/$atxs)

### Top Social Posts [#](/topic/$4521t/posts)
---
Top posts by engagements in the last XX hours

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

": @AstriaTx licensed its HAE treatment Navenibart to Kaken Pharmaceutical for the Japanese market. It is a kallikrein inhibitor that is in phase X and is dosed up to every six months. $ATXS Full video:"  
[X Link](https://x.com/BiotechTV/status/1953537900907294759) [@BiotechTV](/creator/x/BiotechTV) 2025-08-07T19:25Z 9438 followers, 1832 engagements


"Alumis lead candidate ESK-001 is a potential best-in-class allosteric TYK2 inhibitor for immune-mediated diseases like plaque psoriasis and SLE. Just last month Kaken Pharmaceutical inked a $40M+ licensing deal for rights in Japanunderscoring confidence in this promising next-generation TYK2 inhibitor. Read more:"  
[X Link](https://x.com/drughunter_com/status/1920138003516690463) [@drughunter_com](/creator/x/drughunter_com) 2025-05-07T15:25Z 10.7K followers, 6383 engagements


"$ALMS Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan"  
[X Link](https://x.com/AskEdgarIO/status/1904514065466012131) [@AskEdgarIO](/creator/x/AskEdgarIO) 2025-03-25T12:41Z 2303 followers, XXX engagements